In recent years, enzymatic DNA synthesis technology has achieved significant progress in the fields of cell and gene therapy (CGT) as well as vaccine development. This innovative method aims to gradually replace traditional plasmid DNA production by providing high-quality and high-purity synthetic DNA. Compared with plasmid DNA, enzymatically synthesized DNA offers higher scalability, lower impurity risk, and more flexible design capabilities, making it an ideal choice for clinical trials and therapeutic applications. It is widely used in various cutting-edge biotechnology fields, including adeno-associated virus (AAV) vector production, lentiviral vector construction, DNA vaccine development, mRNA therapy and vaccine preparation, as well as the design of gene editing tools based on technologies such as CRISPR.

The novel synthetic DNA technology developed by 4basebio has made breakthrough progress in the field of genetic engineering, successfully overcoming many bottlenecks and challenges faced by current plasmids and other traditional DNA technologies. Traditional DNA production usually relies on biotechnological methods such as bacterial fermentation. Although these methods are mature, they have obvious limitations, such as long production cycles, complex quality control, and difficulty in meeting large-scale customized needs. In contrast, 4basebio’s fully enzymatic production process completely eliminates reliance on living cells. Through the precise design and regulation of enzymatic reactions, it achieves a high degree of controllability over the DNA synthesis process. This method not only enables the production of longer and more complex DNA sequences but also ensures the purity and stability of the final product, thereby better supporting the diverse needs in gene therapy and vaccine development. In addition to high efficiency and high yield, this new technology significantly shortens the production cycle, reducing the batch delivery time of DNA from months to weeks. This greatly improves R&D efficiency and reduces time costs.

Advantages of 4basebio’s Synthetic DNA Over Traditional Plasmid DNA

· Greater Cost-Effectiveness: Reduces labor and material costs, simplifies the process flow, and achieves lower overall costs and higher quality control through patented enzyme technology.

· Enhanced Safety: No bacterial backbone, no antibiotic resistance genes, low risk of endotoxin contamination, and no host cell contaminants.

· Flexible and Controllable Production Scale: Single-batch production is controllable from microgram (μg) to gram (g) levels, suitable for rapid screening of multiple constructs, and free from batch failure risks.

· Efficient and Rapid DNA Acquisition: Based on a fast and high-yield enzymatic process, it eliminates the need for cell bank establishment and complex processes. With standardized downstream processing (DSP) production, its yield is twice that of plasmid DNA.

· Compatibility with Multiple Applications: Four types of DNA constructs meet diverse application needs.

· Sequence Flexibility: Suitable for complex sequences (e.g., ITRs, poly A tails), long sequences of ≥10 kb, and sequences toxic to bacteria.

4basebio’s novel synthetic DNA technology has a wide range of applications, covering multiple stages from basic scientific research to clinical trials. For example, in the development of gene editing tools, high-quality linear DNA constructs can serve as ideal vectors or templates; in the field of vaccine R&D, the rapid generation of DNA with specific sequences can significantly accelerate the speed of antigen screening and verification. Therefore, this innovation by 4basebio not only improves the overall level of DNA synthesis technology but also provides strong technical support for promoting the development of global health initiatives.

4basebio offers four types of linear DNA constructs tailored to different application directions.

hpDNA——For Viral Vector or Non-Viral Vector Production

This DNA construct is particularly suitable for application in viral vector or non-viral vector production. It enables efficient generation of complex sequences (such as ITRs, LTRs, etc.) while effectively avoiding the risk of sequence deletion or recombination, thereby ensuring sequence integrity. In addition, since the construct contains no bacterial-derived sequences, it can eliminate the risk of reverse packaging.

opDNA——For mRNA Vaccine and Therapeutic Drug Production

DNA templates with an open 3’-end design are highly suitable for in vitro transcription, enabling the production of high-quality mRNA suitable for vaccine development and therapeutic drug applications. By directly encoding a continuous poly(A) tail into the DNA template, the post-transcriptional polyadenylation step can be omitted, thereby simplifying the production process. Additionally, open DNA (opDNA) technology ensures the generation of homogeneous and high-purity mRNA products.

oeDNA——In Vivo Applications

Open DNA constructs can generate blunt ends, overhangs, or any combination of the two. Similar to 4basebio’s other DNA products, open DNA possesses the property of resistance to exonuclease degradation, thus exhibiting high stability and applicability in in vivo applications.

ssDNA——In Vitro and In Vivo Applications

Single-stranded DNA (ssDNA) is a linear single-stranded DNA molecule. Both its 3'- and 5'-ends possess the ability to resist exonuclease degradation, thus exhibiting high stability and applicability in both in vitro experiments and in vivo applications.

As a company focused on gene therapy and delivery solutions, 4basebio leverages its advanced technologies and deep expertise to provide customers with one-stop support, ranging from raw material supply to process optimization. Whether you need to ensure the quality stability of DNA products or aim to improve the delivery efficiency of genetic payloads to target cells, 4basebio can tailor solutions to specific needs, helping customers accelerate the R&D process of therapeutic regimens.

 With the growing global demand for personalized medicine and high-efficiency vaccines, the application prospects of enzymatic DNA synthesis technology have become increasingly broad. This technology not only helps reduce production costs but also improves product quality and consistency, thereby better meeting the stringent requirements of clinical trials and commercial production. The advancement of this technology is redefining the standards for gene therapy and vaccine development, laying a solid foundation for future medical innovation.

Beijing XMJ Technology Co., Ltd. is the exclusive distributor of 4basebio in China. For inquiries regarding 4basebio’s services, please feel free to call XMJ’s customer service hotline at 400-050-4006 or visit the official website at www.emergexcelerate.com for more information.